Abstract
The classification of mature NK-/T-cell lymphoma mainly originating from the T-cell lineage with predominantly nodal involvement and Epstein–Barr virus (EBV) positivity in a majority of tumor cells is unresolved. We analyzed the clinical features and treatment outcomes of such patients. Five patients with EBV-positive nodal T-cell lymphoma were surveyed during follow-up period. The median age was 53 years (range 33–88 years), and all patients showed nodal involvement. The patients mostly presented advanced clinical features, such as stage III or IV disease, elevated lactate dehydrogenase, and hemophagocytosis. Four patients received cyclophosphamide-containing chemotherapy at the time of diagnosis. However, three patients (75 %) showed disease progression during the early cycles of initial treatment. The median overall survival was 1.5 months (95 % CI 0.0–3.4 months). Patients with EBV-positive nodal T-cell lymphoma mainly show lymph node involvement, but also show aggressive clinical features and poor treatment outcomes, such as aggressive NK-cell leukemia. Therefore, we should consider EBV-positive nodal T-cell lymphoma to be a unique disease entity distinct from peripheral T-cell lymphoma not otherwise specified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asano N, Kato S, Nakamura S. Epstein–Barr virus-associated natural killer/T-cell lymphomas. Best Pract Res Clin Haematol. 2013;26:15–21.
Takahashi E, Asano N, Li C, Tanaka T, Shimada K, Shimada S, et al. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology. 2008;52:585–96.
Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010;92:697–701.
Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
Beaven AW, Diehl LF. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematol Am Soc Hematol Educ Program. 2015;2015:550–8.
Lunning MA. Treatment of peripheral T-cell lymphoma: many shades of gray. Oncology (Williston Park). 2015;29:545–50.
Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, et al. The Epstein–Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment. Curr Hematol Malig Rep. 2015;10:456–67.
Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein–Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108:4163–9.
Jeon YK, Kim JH, Sung JY, Han JH, Ko YH, Hematopathology Study Group of the Korean Society of P. Epstein–Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features. Hum Pathol. 2015;46:981–90.
Kato S, Asano N, Miyata-Takata T, Takata K, Elsayed AA, Satou A, et al. T-cell receptor (TCR) phenotype of nodal Epstein–Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases. Am J Surg Pathol. 2015;39:462–71.
Kato S, Takahashi E, Asano N, Tanaka T, Megahed N, Kinoshita T, et al. Nodal cytotoxic molecule (CM)-positive Epstein–Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases. Histopathology. 2012;61:186–99.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-Cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240–6.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126:17–25.
Pail JH, Choe JY, Kim H, Lee JO, Kang HJ, Jeon YK, et al. Clinicopathological categorization of Epstein–Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leuk Lymphoma. 2016;9:1–11.
Kato S, Miyata T, Takata K, Shimada S, Ito Y, Nakamura S, et al. Epstein–Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein–Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report. Hum Pathol. 2013;44:2849–52.
Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Komatsu N, et al. T/NK cell type chronic active Epstein–Barr virus disease in adults: an underlying condition for Epstein–Barr virus-associated T/NK-cell lymphoma. J Clin Pathol. 2012;65:278–82.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.
Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica. 2002;87:1343–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have stated that they have no conflicts of interest.
About this article
Cite this article
Jung, K.S., Cho, SH., Kim, S.J. et al. Clinical features and treatment outcome of Epstein–Barr virus-positive nodal T-cell lymphoma. Int J Hematol 104, 591–595 (2016). https://doi.org/10.1007/s12185-016-2068-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-016-2068-1